Avita Medical – Positive ReCell repigmentation trial results
Australia, 11 June 2014. ASX announcement here.
Nexvet to present key data on use of species-specific monoclonal antibodies in management of chronic pain in dogs
/in Pharmamark, Portfolio CompaniesMELBOURNE, Australia – June 05, 2014 – Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the oral presentation of data related to clinical development of NV-01, a … Down load article here.
Nexus6 Receives FDA Clearance for Latest Smartinhaler
/in Adherium, Portfolio CompaniesNexus6 Ltd, has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for its new SmartTouch inhaler monitoring device. June 3rd, 2014. Link here. It is well known that it is difficult for patients to remember to take daily preventative medications over a long term as required for the management of many chronic […]
SeaDragon poised for significant growth
/in Portfolio Companies, SeaDragonNZX & Media Release 30 May 2014. Link here. Financial results for the year to 31 March 2014 Highlights: • Significant new squalene sales contract demonstrates the benefits of a secure raw material supply • Making good progress on the new refined fish oil plant in Nelson • Financially well positioned with $5.2m of cash on hand […]
AmpliPhi Announces Appointment of New Board Member
/in Armata Pharmaceuticals, Portfolio CompaniesRICHMOND, VA, US, LJUBLJANA, SLOVENIA and SYDNEY, AUSTRALIA, May 22, 2014 Link here. AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that Wendy Johnson has been appointed to its Board of Directors effective May 19, 2014. Ms. Johnson will stand for election […]
AmpliPhi Announces Appointment of New Board Member – Wendy Johnson
/in Armata Pharmaceuticals, Portfolio CompaniesLink here. RICHMOND, VA, US, LJUBLJANA, SLOVENIA and SYDNEY, AUSTRALIA, May 22, 2014 –AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that Wendy Johnson has been appointed to its Board of Directors effective May 19, 2014. Ms. Johnson will stand for election to […]
Avita Medical appoints new Chairman
/in Avita Medical, Portfolio CompaniesAustralia, 20 May 2014. Link here. Read more about Avita Medical appoints new Chairman
ReCell® Spray-on Skin® demonstrates superior results treating hypopigmentation in aesthetic plastic surgery trial
/in Avita Medical, Portfolio CompaniesLink here. Highlights · Clinical study interim results demonstrate ReCell® superiority as treatment for hypopigmentation. · Statistically significant pigment restored in patients’ hypopigmented scars treated with ReCell. · Results support the Company’s commercial strategy for use of ReCell in aesthetic plastic surgery. · Study results delivered at key European conferences, enhancing ReCell industry profile. Northridge, Calif., […]
Union MedTech plc raises £10 million to commercialise and develop REX, a hands-free robotic exoskeleton
/in Portfolio Companies, Rex BionicsMay 2, 2014. Link here. Company to be admitted to AIM with a market capitalisation of £25.7 million Union MedTech plc today announces it is to be admitted to the AIM market of the London Stock Exchange with a market capitalisation of £25.7 million. On Admission, the acquisition by Union MedTech of REX Bionics Limited (“REX […]
NEXVET ANNOUNCES US$31.5 MILLION FINANCING
/in Pharmamark, Portfolio CompaniesNEXVET ANNOUNCES US$31.5 MILLION FINANCING U.S. Institutional Investors Lead Oversubscribed Round To Advance Monoclonal Antibody Clinical Programs For Companion Animal Health MELBOURNE, Australia–April 16, 2014 –Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top–‐tier U.S.–‐based institutional investors Farallon Capital Management, LLC, Adage […]